TY - JOUR
T1 - Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy
AU - Freedland, Stephen J.
AU - Choeurng, Voleak
AU - Howard, Lauren
AU - De Hoedt, Amanda
AU - du Plessis, Marguerite
AU - Yousefi, Kasra
AU - Lam, Lucia L.
AU - Buerki, Christine
AU - Ra, Seong
AU - Robbins, Bruce
AU - Trabulsi, Edouard J.
AU - Shah, Nikhil L.
AU - Abdollah, Firas
AU - Feng, Felix Y.
AU - Davicioni, Elai
AU - Dicker, Adam P.
AU - Karnes, Robert J.
AU - Den, Robert B.
N1 - Publisher Copyright:
© 2016 European Association of Urology
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after radical prostatectomy (RP), some patients still progress to metastases. Identifying these men would allow them to undergo systemic therapy including testing novel therapies to reduce metastases risk. Objective To test whether the genomic classifier (GC) predicts development of metastatic disease. Design, setting, and participants Retrospective multi-center and multi-ethnic cohort study from two academic centers and one Veterans Affairs Medical Center in the United States involving 170 men receiving SRT for recurrent PCa post-RP. Outcome measurements and statistical analysis Time from SRT to development of metastatic disease tested using Cox regression, survival c-index, and decision curve analysis. Performance of GC was compared to the Cancer of the Prostate Risk Assessment Score and Briganti risk models based on these metrics. Results and limitations With a median 5.7 yr follow-up after SRT, 20 patients (12%) developed metastases. On multivariable analysis, for each 0.1 unit increase in GC (scaled from 0 to 1), the hazard ratio for metastasis was 1.58 (95% confidence interval 1.16–2.17; p = 0.002). Adjusting for androgen deprivation therapy did not materially change the results. The c-index for GC was 0.85 (95% confidence interval 0.73–0.88) versus 0.63–0.65 for published clinico-pathologic risk models. The 5-yr cumulative incidence of metastasis post-SRT in patients with low, intermediate, and high GC scores was 2.7%, 8.4%, and 33.1%, respectively (p < 0.001). Conclusions While validation in larger, prospectively collected cohorts is required, these data suggest GC is a strong predictor of metastases among men receiving SRT for recurrent PCa post-RP, accurately identifying men who are excellent candidates for systemic therapy due to their very high-risk of metastases. Patient summary Genomic classifier and two clinico-pathologic risk models were evaluated on their ability to predict metastases among men receiving salvage radiation therapy for recurrent prostate cancer. Genomic classifier was able to identify candidates for further therapies due to their very high-risk of metastases.
AB - Background Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after radical prostatectomy (RP), some patients still progress to metastases. Identifying these men would allow them to undergo systemic therapy including testing novel therapies to reduce metastases risk. Objective To test whether the genomic classifier (GC) predicts development of metastatic disease. Design, setting, and participants Retrospective multi-center and multi-ethnic cohort study from two academic centers and one Veterans Affairs Medical Center in the United States involving 170 men receiving SRT for recurrent PCa post-RP. Outcome measurements and statistical analysis Time from SRT to development of metastatic disease tested using Cox regression, survival c-index, and decision curve analysis. Performance of GC was compared to the Cancer of the Prostate Risk Assessment Score and Briganti risk models based on these metrics. Results and limitations With a median 5.7 yr follow-up after SRT, 20 patients (12%) developed metastases. On multivariable analysis, for each 0.1 unit increase in GC (scaled from 0 to 1), the hazard ratio for metastasis was 1.58 (95% confidence interval 1.16–2.17; p = 0.002). Adjusting for androgen deprivation therapy did not materially change the results. The c-index for GC was 0.85 (95% confidence interval 0.73–0.88) versus 0.63–0.65 for published clinico-pathologic risk models. The 5-yr cumulative incidence of metastasis post-SRT in patients with low, intermediate, and high GC scores was 2.7%, 8.4%, and 33.1%, respectively (p < 0.001). Conclusions While validation in larger, prospectively collected cohorts is required, these data suggest GC is a strong predictor of metastases among men receiving SRT for recurrent PCa post-RP, accurately identifying men who are excellent candidates for systemic therapy due to their very high-risk of metastases. Patient summary Genomic classifier and two clinico-pathologic risk models were evaluated on their ability to predict metastases among men receiving salvage radiation therapy for recurrent prostate cancer. Genomic classifier was able to identify candidates for further therapies due to their very high-risk of metastases.
KW - Genomic classifier
KW - Metastasis
KW - Prognosis
KW - Prostate cancer
KW - Salvage radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=84955479456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955479456&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2016.01.008
DO - 10.1016/j.eururo.2016.01.008
M3 - Article
C2 - 26806658
AN - SCOPUS:84955479456
SN - 0302-2838
VL - 70
SP - 588
EP - 596
JO - European urology
JF - European urology
IS - 4
ER -